Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Former Abbott Drug Unit Recalls Synthroid Again

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2013 | 09:36pm CET

Abbott Laboratories' (>> Abbott Laboratories) former pharmaceutical unit, now spun off as AbbVie Inc. (>> AbbVie Inc), recently recalled more than 28,520 bottles of the thyroid-hormone replacement therapy Synthroid over a dose mix-up, marking the second recall of the drug in six months.

One lot of 150-microgram Synthroid tablets was recalled because one bottle was found to contain lower-dose, 75-microgram tablets, AbbVie spokesman Gregory Miley said Friday. The voluntary recall was initiated in early December as a precaution, he said.

The cause was a "manufacturing line clearance error," he said, and AbbVie has taken corrective action. The company isn't aware of any increase in patient complaints or adverse events associated with the label error.

AbbVie was spun off to Abbott shareholders as an independent company at the start of January. AbbVie assumed Synthroid's U.S. marketing rights, though Abbott Labs continues to market the drug outside the U.S.

In July, Abbott recalled three lots of Synthroid because some bottles had defects that could affect the stability of the tablets at the end of shelf life. More than 136,500 bottles of Synthroid were subject to that recall, though Abbott said a majority of them remained under Abbott's control and weren't shipped out.

Both Synthroid recalls were classified by the FDA as Class II, which is typically applied in situations where a product might cause a temporary health problem or pose only a slight threat of a serious health problem.

Synthroid is a synthetic thyroid hormone used by people with hypothyroidism, in which the thyroid gland doesn't produce enough natural thyroid hormone.

Abbott reported $461 million of global Synthroid sales for the first nine months of 2012.

AbbVie shares were recently down a penny at $33.61.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, AbbVie Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
02/23 ABBOTT LABORATORIES : Special Notice - 65-- Abbott Cath Supplies- Intent to Sole..
02/21 ABBOTT : Commences Exchange Offers and Consent Solicitations for St. Jude Medica..
02/21 ABBOTT LABORATORIES (NYSE : ABT) Files An 8-K Financial Statements and Exhibits
02/21 ABBOTT LABORATORIES : Completion of Acquisition or Disposition of Assets, Financ..
02/20 ABBOTT LABORATORIES PAKISTAN : Board meeting of Abbott Laboratories (Pakistan) L..
02/20 ABBOTT LABORATORIES (NYSE : ABT) Files An 8-K Departure of Directors or Certain ..
02/17 ABBOTT LABORATORIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
02/17 ABBOTT LABORATORIES : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
02/17 ABBOTT : Declares 373rd Consecutive Quarterly Dividend
02/15 ABBOTT LABORATORIES : Real-World Data from Abbott's FreeStyle® Libre Show Associ..
More news
Sector news : Pharmaceuticals - NEC
12:59a Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
02/23DJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
02/23DJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/23 S&P Aristocrat Dog 'Safe' Yields For February Piloted By AbbVie, Chevron, And..
02/22 Free Market Capitalist January Dividend Income
02/21 Abbott launches exchange offer for $3.1B in St. Jude debt
02/20 THE DIVIDEND GROWTH PORTFOLIO TO GRO : Is It Time To Stock Up On Cash?
02/17 Abbott Laboratories declares $0.265 dividend
Advertisement
Financials ($)
Sales 2017 26 126 M
EBIT 2017 5 738 M
Net income 2017 3 771 M
Debt 2017 18 620 M
Yield 2017 2,27%
P/E ratio 2017 19,89
P/E ratio 2018 17,00
EV / Sales 2017 3,69x
EV / Sales 2018 3,43x
Capitalization 77 777 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 47,5 $
Spread / Average Target 5,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Randel W. Woodgrift VP-Vascular, Manufacturing, Research & Development
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES17.18%77 777
JOHNSON & JOHNSON3.86%325 158
ROCHE HOLDING LTD.5.98%210 992
PFIZER INC.3.51%203 836
NOVARTIS AG3.51%202 566
MERCK & CO., INC.11.23%180 014
More Results